9 research outputs found
Linear separability in superordinate natural language concepts.
Two experiments are reported in which linear separability was investigated in superordinate natural language concept pairs (e.g., toiletry-sewing gear). Representations of the exemplars of semantically related concept pairs were derived in two to five dimensions using multidimensional scaling (MDS) of similarities based on possession of the concept features. Next, category membership, obtained from an exemplar generation study (in Experiment 1) and from a forced-choice classification task (in Experiment 2) was predicted from the coordinates of the MDS representation using log linear analysis. The results showed that all natural kind concept pairs were perfectly linearly separable, whereas artifact concept pairs showed several violations. Clear linear separability of natural language concept pairs is in line with independent cue models. The violations in the artifact pairs, however, yield clear evidence against the independent cue models
Dominance, overextensions and the conjunction effect in different syntactic phrasings of concept conjunctions
Two studies are described in which the membership ratings of relative clause descriptions of concept conjunctions (such as pets that are also birds) are compared to membership ratings of adjective-noun and noun-noun phrasings of the same conjunctions. The results show that the different phrasings of the conjunction carry the same meaning as reflected in the membership ratings. Furthermore, it is shown that the different phrasings also result in similar patterns of dominance and overextensions. The results also demonstrate that the extent to which the conjunction effect described by Smith and Osherson (1984; Osherson & Smith, 1982; Smith, Osherson, Rips, & Keane, 1988) is found in the data is related not only to the incompatibility of the constituents, but also to the dominance effect. In summary, our results provide evidence for a unitary representation of conjunctive concepts, regardless of the syntactic phrasing of the conjunction.info:eu-repo/semantics/publishe
Dutch norm data for 13 semantic categories and 338 exemplars
A data set is described that includes eight variables gathered for 13 common superordinate natural language categories and a representative set of 338 exemplars in Dutch. The category set contains 6 animal categories (reptiles, amphibians, mammals, birds, fish, and insects), 3 artifact categories (musical instruments, tools, and vehicles), 2 borderline artifact-natural-kind categories (vegetables and fruit), and 2 activity categories (sports and professions). In an exemplar and a feature generation task for the category nouns, frequency data were collected. For each of the 13 categories, a representative sample of 5-30 exemplars was selected. For all exemplars, feature generation frequencies, typicality ratings, pairwise similarity ratings, age-of-acquisition ratings, word frequencies, and word associations were gathered. Reliability estimates and some additional measures are presented. The full set of these norms is available in Excel format at the Psychonomic Society Web archive, www.psychonomic. org/archive/.status: publishe
Not guppies, nor goldfish, but tumble dryers, Noriega, Jesse Jackson, panties, car crashes, bird books, and Stevie Wonder
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial
Background: Treatment with one standard dose (2 g/kg) of intravenous immunoglobulin is insufficient in a proportion of patients with severe Guillain-Barré syndrome. Worldwide, around 25% of patients severely affected with the syndrome are given a second intravenous immunoglobulin dose (SID), although it has not been proven effective. We aimed to investigate whether a SID is effective in patients with Guillain-Barré syndrome with a predicted poor outcome. Methods: In this randomised, double-blind, placebo-controlled trial (SID-GBS), we included patients (≥12 years) with Guillain-Barré syndrome admitted to one of 59 participating hospitals in the Netherlands. Patients were included on the first day of standard intravenous immunoglobulin treatment (2 g/kg over 5 days). Only patients with a poor prognosis (score of ≥6) according to the modified Erasmus Guillain-Barré syndrome Outcome Score were randomly assigned, via block randomisation stratified by centre, to SID (2 g/kg over 5 days) or to placebo, 7–9 days after inclusion. Patients, outcome adjudicators, monitors, and the steering committee were masked to treatment allocation. The primary outcome measure was the Guillain-Barré syndrome disability score 4 weeks after inclusion. All patients in whom allocated trial medication was started were included in the modified intention-to-treat analysis. This study is registered with the Netherlands Trial Register, NTR 2224/NL2107. Findings: Between Feb 16, 2010, and June 5, 2018, 327 of 339 patients assessed for eligibility were included. 112 had a poor prognosis. Of those, 93 patients with a poor prognosis were included in the modified intention-to-treat analysis: 49 (53%) received SID and 44 (47%) received placebo. The adjusted common odds ratio for improvement on the Guillain-Barré syndrome disability score at 4 weeks was 1·4 (95% CI 0·6–3·3; p=0·45). Patients given SID had more serious adverse events (35% vs 16% in the first 30 days), including thromboembolic events, than those in the placebo group. Four patients died in the intervention group (13–24 weeks after randomisation). Interpretation: Our study does not provide evidence that patients with Guillain-Barré syndrome with a poor prognosis benefit from a second intravenous immunoglobulin course; moreover, it entails a risk of serious adverse events. Therefore, a second intravenous immunoglobulin course should not be considered for treatment of Guillain-Barre syndrome because of a poor prognosis. The results indicate the need for treatment trials with other immune modulators in patients severely affected by Guillain-Barré syndrome. Funding: Prinses Beatrix Spierfonds and Sanquin Plasma Products